Therapeutic Modulation of Lipoprotein-associated Phospholipase A2 (Lp-PLA2)

By  

Current Pharmaceutical Design, Vol. 17, Iss. 33, 2011-11 ,pp. : 3656-3661

Bentham Science Publishers

Access to resources Recommend Favorite

Pathophysiological Role and Clinical Significance of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Bound to LDL and HDL

By  

Current Pharmaceutical Design, Vol. 20, Iss. 40, 2014-12 ,pp. : 6256-6269

Bentham Science Publishers

Access to resources Recommend Favorite

Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin

By Li Qing   Chen Bi-Lian   Ozdemir Vural   Ji Wei   Mao Yan-Mei   Wang Lian-Ci   Lei Hei-Ping   Fan Lan   Zhang Wei   Liu Jie   Zhou Hong-Hao  

Pharmacogenomics, Vol. 8, Iss. 6, 2007-06 ,pp. : 577-586

Future Medicine

Access to resources Recommend Favorite

Over-expression of caveolin-1 aggravate LPS-induced inflammatory response in AT-1 cells via up-regulation of cPLA2/p38 MAPK

By Lv Xue-Jun   Li Yu-Ying   Zhang Yong-Juan   Mao Mei   Qian Gui-Sheng  

Inflammation Research, Vol. 59, Iss. 7, 2010-07 ,pp. : 531-541

Springer Publishing Company

Access to resources Recommend Favorite

Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with α-glucosidase inhibitors

By Masuda Kiyomi   Aoki Kazutaka   Kamiko Kazunari   Takihata Masahiro   Ito Yuzuru   Nagakura Mieko   Kawasaki Satsuki   Akema Noriko   Hasegawa Maki   Nakajima Shigeru   Shinoda Kazuaki   Toumura Shyoken   Tsunoda Seishi   Enomoto Hitoshi   Shimotomai Hidefumi   Terauchi Yasuo  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 9, 2013-06 ,pp. : 1111-1118

Informa Healthcare

Access to resources Recommend Favorite